---
schema_version: "secwatch.filing_event.v1"
accession: "0001651308-24-000021"
form_type: "8-K"
ticker: "ONC"
cik: "0001651308"
company_name: "BeOne Medicines Ltd."
filed_at: "2024-03-08T23:59:59+00:00"
generated_at: "2026-06-05T00:34:07.190714+00:00"
event_type: "litigation"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# BeiGene files patent suits against Sandoz and MSN to block generic BRUKINSA until 2034

## Summary
- Filed Hatch-Waxman infringement suits in District of New Jersey after Sandoz and MSN filed ANDAs with Paragraph IV certifications.
- Composition of matter patent for BRUKINSA not challenged; remains intact and expires in 2034.
- Complaints seek permanent injunction to prevent generic commercialization before expiration of asserted Orange Book patents.
- ANDA litigation common in pharma; additional notices from other generic companies may follow.

## SEC filing metadata
- accession: 0001651308-24-000021
- form_type: 8-K
- ticker: ONC
- cik: 0001651308
- company_name: BeOne Medicines Ltd.
- filed_at: 2024-03-08T23:59:59+00:00
- event_type: litigation
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1651308/000165130824000021/0001651308-24-000021-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1651308/000165130824000021/bgne-20240308.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001651308-24-000021
- JSON: https://secwatch.observer/filing/0001651308-24-000021.json
- Plain text: https://secwatch.observer/filing/0001651308-24-000021.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.